Copay help by condition · Kidney and urologic · read 2026-11-08
Chronic Kidney Disease (CKD): which charitable copay funds are open
All 2 funds we hold for Chronic Kidney Disease are closed or at capacity right now (read 2026-11-08).
Funds fill and reopen. Use the alert below, ask the manufacturer's program for your drug (see the assistance finder), and check your state's Medicaid coverage.
If you have Medicare Part D: CMS prints the annual out-of-pocket threshold as $2,400 in 2027 ($2,100 in 2026) (Table V-2 of its CY 2027 announcement). It is a benefit parameter and applies to covered drugs under plan rules. What changes on January 1.
Swipe to read across
A copy for a patient, a clinic or a pharmacist, with each source and the date we read it.
Every fund we hold for Chronic Kidney Disease
- Closed or at capacityChronic Kidney Disease
Good Days ·
Award level: not statedInsurance supported: not stated
The page marks the fund as seeking funds for new enrollments (the fund's list item on the page carries the class seeking), so it is not open to applications. Source page
- Closed or at capacityChronic kidney disease (CKD)
TotalAssist (Patient Advocate Foundation copay funds) ·
Award level: $4,800Insurance supported: Medicaid, Medicare, TRICARE
The page lists the fund as Closed. Source page
Drugs whose FDA label names Chronic Kidney Disease
7 drugs. Each row quotes the sentence of the drug's FDA label (Indications and Usage, openFDA) that names the condition. A label naming a condition is not a statement that the drug is approved, effective or covered for you. Dashes in quotes are shown as hyphens. Of these, 5 have a program (in our assistance finder or on the program's own page) and 3 have a Medicare negotiated price in the CMS file; an empty cell says we found nothing in our data, not that nothing exists.
| Drug | What the FDA label says | Manufacturer program | Medicare negotiated price |
|---|---|---|---|
| Farxiga Dapagliflozin Every route for this drug | To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular (CV) death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression. A sentence about reducing the risk of this condition. Label on openFDA, read 2026-11-10 | Farxiga Savings (via AstraZeneca) Heart Medication Assistance (Multiple Programs) Diabetes Medication Assistance (Multiple Programs) AZ&Me Prescription Savings Program Not in its current list The program's page printed this drug in an earlier list and not in its current one. | $183.33 for a 30-day supply, effective 2027-01-01 |
| Jardiance Empagliflozin Every route for this drug | ... to reduce the risk of sustained decline in eGFR, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression. A sentence about reducing the risk of this condition. Label on openFDA, read 2026-11-10 | Jardiance Savings (via Boehringer Ingelheim/Lilly) Heart Medication Assistance (Multiple Programs) Diabetes Medication Assistance (Multiple Programs) and 1 more | $202.33 for a 30-day supply, effective 2027-01-01 |
| Ozempic Semaglutide Every route for this drug | ... to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease. A sentence about reducing the risk of this condition. Label on openFDA, read 2026-11-10 | Ozempic Savings (via NovoCare) Limited Novo Nordisk PAP (NovoCare) Limited 0.5 mg, 1 mg, or 2 mg Diabetes Medication Assistance (Multiple Programs) | $274.00 for a 30-day supply, effective 2027-01-01 |
| Synjardy XR, Synjardy Empagliflozin/Metformin Hcl Every route for this drug | Sustained decline in eGFR, end-stage kidney disease, CV death, and hospitalization in adults with chronic kidney disease at risk of progression. Label on openFDA, read 2026-11-10 | Boehringer Ingelheim Cares Foundation Limited | not in the CMS negotiated-price file |
| Kerendia Finerenone Every route for this drug | ... cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2DM). Label on openFDA, read 2026-11-10 | Bayer US Patient Assistance Foundation (program page) | not in the CMS negotiated-price file |
| Auryxia Ferric Citrate | Ferric citrate tablets are a phosphate binder indicated for the control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis. Label on openFDA, read 2026-11-10 | not in our assistance finder | not in the CMS negotiated-price file |
| Xphozah Tenapanor Hcl | XPHOZAH is indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. Label on openFDA, read 2026-11-10 | not in our assistance finder | not in the CMS negotiated-price file |
Related conditions
No broader or more specific condition page for this one.
Group: Kidney and urologic. All conditions: the condition index. Fund board for every condition: charitable copay fund status.
What changed
First read on 2026-11-08. We keep each read with its date, so a fund reopening or closing will show here as a change. Until we have a second read there is nothing to compare, and we do not guess. The read date of every source is on the changes page.
This page as data
The same facts as JSON, each fund with its source URL and read date: chronic-kidney-disease.json. Edition 2026-11, root 006ab9a329709cbe. See the licence page.
Questions
Is there an open charitable copay fund for Chronic Kidney Disease?
As read on 2026-11-08, none of the 2 funds we hold for Chronic Kidney Disease say they are open. Funds reopen, so use the alert on this page.
Which organizations run funds for Chronic Kidney Disease?
Good Days and TotalAssist (Patient Advocate Foundation copay funds). Each fund row on this page links to the organization's own page.
Does an open fund mean I qualify?
No. A status says whether a fund is taking applications. Eligibility, award level and which insurance it supports are each fund's own rules; where the page states them they are shown on the fund.
How current is this page?
Statuses are what each fund's own page said on the date we read it (2026-11-08). We do not promise a fund is still in that state today.